HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reynolds, M. G. Articles by Roos, D. S. Search for Related Content PubMed PubMed Citation Articles by Reynolds, M. G. Articles by Roos, D. S. Social Bookmarking                      What's this?

J Biol Chem, Vol. 273, Issue 6, 3461-3469, February 6, 1998

A Biochemical and Genetic Model for Parasite Resistance to Antifolates
TOXOPLASMA GONDII PROVIDES INSIGHTS INTO PYRIMETHAMINE AND CYCLOGUANIL RESISTANCE IN PLASMODIUM FALCIPARUM

From the Department of Biology, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6018

We have exploited the experimental accessibility of the protozoan parasite Toxoplasma gondii and its similarity to Plasmodium falciparum to investigate the influence of specific dihydrofolate reductase polymorphisms known from field isolates of drug-resistant malaria. By engineering appropriate recombinant shuttle vectors, it is feasible to examine mutations by transient or stable transformation of T. gondii parasites, in bacterial and yeast complementation assays, and through biochemical analysis of purified enzyme. A series of mutant alleles that mirror P. falciparum variants reveals that the key mutation Asn-108 (Asn-83 in T. gondii) probably confers resistance to pyrimethamine by affecting critical interactions in the ternary complex. Mutations such as Arg-59 (T. gondii 36) have limited effect in isolation, but in combination with other mutations they enhance the competitive ability of folate by increasing the speed of product turnover. Val-16 (T. gondii 10) confers low level resistance to cycloguanil but hypersensitivity to pyrimethamine. This mutation precludes Asn-108, probably because compression of the folate binding pocket introduced by this combination is incompatible with enzyme function. These studies permit detailed biochemical, kinetic, and structural analysis of drug resistance mutations and reconstruction of the probable phylogeny of antifolate resistance in malaria.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				P. Meneceur, M.-A. Bouldouyre, D. Aubert, I. Villena, J. Menotti, V. Sauvage, J.-F. Garin, and F. Derouin In Vitro Susceptibility of Various Genotypic Strains of Toxoplasma gondii to Pyrimethamine, Sulfadiazine, and Atovaquone Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1269 - 1277. [Abstract] [Full Text] [PDF]

				S. KRUDSOOD, S. N. PATEL, N. TANGPUKDEE, W. THANACHARTWET, W. LEOWATTANA, K. PORNPININWORAKIJ, A. K. BOGGILD, S. LOOAREESUWAN, and K. C. KAIN EFFICACY OF ATOVAQUONE-PROGUANIL FOR TREATMENT OF ACUTE MULTIDRUG-RESISTANT PLASMODIUM FALCIPARUM MALARIA IN THAILAND Am J Trop Med Hyg, April 1, 2007; 76(4): 655 - 658. [Abstract] [Full Text] [PDF]

				A. K. BOGGILD, M. E. PARISE, L. S. LEWIS, and K. C. KAIN ATOVAQUONE-PROGUANIL: REPORT FROM THE CDC EXPERT MEETING ON MALARIA CHEMOPROPHYLAXIS (II) Am J Trop Med Hyg, February 1, 2007; 76(2): 208 - 223. [Abstract] [Full Text] [PDF]

				B. A. Butcher and E. Y. Denkers Mechanism of Entry Determines the Ability of Toxoplasma gondii To Inhibit Macrophage Proinflammatory Cytokine Production Infect. Immun., September 1, 2002; 70(9): 5216 - 5224. [Abstract] [Full Text] [PDF]

				R. G. K. Donald, J. Allocco, S. B. Singh, B. Nare, S. P. Salowe, J. Wiltsie, and P. A. Liberator Toxoplasma gondii Cyclic GMP-Dependent Kinase: Chemotherapeutic Targeting of an Essential Parasite Protein Kinase Eukaryot. Cell, June 1, 2002; 1(3): 317 - 328. [Abstract] [Full Text] [PDF]

				M. G. Reynolds, J. Oh, and D. S. Roos In Vitro Generation of Novel Pyrimethamine Resistance Mutations in the Toxoplasma gondii Dihydrofolate Reductase Antimicrob. Agents Chemother., April 1, 2001; 45(4): 1271 - 1277. [Abstract] [Full Text]

				H. Lau, J. T. Ferlan, V. H. Brophy, A. Rosowsky, and C. H. Sibley Efficacies of Lipophilic Inhibitors of Dihydrofolate Reductase against Parasitic Protozoa Antimicrob. Agents Chemother., January 1, 2001; 45(1): 187 - 195. [Abstract] [Full Text]

				M. G. Reynolds Compensatory Evolution in Rifampin-Resistant Escherichia coli Genetics, December 1, 2000; 156(4): 1471 - 1481. [Abstract] [Full Text]

				D. A. Fidock, T. Nomura, and T. E. Wellems Cycloguanil and Its Parent Compound Proguanil Demonstrate Distinct Activities against Plasmodium falciparum Malaria Parasites Transformed with Human Dihydrofolate Reductase Mol. Pharmacol., December 1, 1998; 54(6): 1140 - 1147. [Abstract] [Full Text]